SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India shines on entering into strategic partnership with Greenko ZeroC

03 Jan 2023 Evaluate

Granules India is currently trading at Rs. 329.30, up by 8.95 points or 2.79% from its previous closing of Rs. 320.35 on the BSE.

The scrip opened at Rs. 322.70 and has touched a high and low of Rs. 329.35 and Rs. 322.00 respectively. So far 9504 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 331.80 and Rs. 314.00 respectively. The current market cap of the company is Rs. 7753.84 crore.

The promoters holding in the company stood at 41.93%, while Institutions and Non-Institutions held 26.67% and 31.40% respectively.

Granules India has entered into a strategic partnership with Greenko ZeroC to collaborate for Green Molecule Solutions and its wider applications in pharmaceuticals to build a leadership position in sustainability and circular economy initiatives and be a pioneer in the industry.

Granules & Greenko ZeroC will develop and promote State-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh. Granules will build a green field facility based on sustainability principles for large scale manufacturing of key starting materials (KSMs), Intermediates, APIs and fermentation-based products. The facility spread across 100 acres, will be commissioned in a phase wise manner. The estimated cost of the project will be approximately Rs 2,000 crore over five years.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

663.75 9.35 (1.43%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×